Axogen, Inc. announced the resignation of Angelo Scopelianos as Chief Research and Development Officer, effective March 31, 2024, and the appointment of Stacy Arnold as his replacement. Scopelianos will provide consulting services until December 31, 2024, and will receive a monthly fee of $9,079.16. He will also be entitled to a one-time additional payment of $75,000 if he continues to provide services through October 1, 2024. Scopelianos will receive his 2023 bonus of $228,385.26 on March 15, 2024. Unvested stock options will continue to vest, unvested restricted stock units will cease vesting, and any vested performance stock units will settle based on the company's goals. Scopelianos is subject to non-competition and other restrictive covenant obligations. Stacy Arnold will assume Scopelianos' product development responsibilities.